How Effective is Dexpak Taperpak Versus Cancer?

ByShaun Snapp

Executive Summary

  • Dexpak Taperpak is one of many chemotherapy drugs.
  • What you will not hear at a cancer center or from your oncologist is how effective is Dexpak Taperpak.  

Introduction

When Dexpak Taperpak is recommended as a treatment, patients do not know and are not told how effective the drug is against cancer. All patients should know the answer to this question, at least generally, rather than simply “trusting one’s doctor.”

Chemotherapy Always Benefits the Cancer Center

Cancer centers significantly mark up chemotherapy drugs, which I cover in the article The Absurd Markup of Over 300% on Average For Chemotherapy Drugs.

It is always very profitable for the chemotherapy center when the patient agrees to use Dexpak Taperpak. Due to the margins involved in chemo drugs for cancer centers and other associated charges, cancer centers are not a good source of information on whether Dexpak Taperpak is a good drug for patients.

How the Cancer Industry Hides the Effectiveness Level of Chemotherapy Treatment

The brutal reality is that the vast majority of chemotherapy drugs that get FDA approval do nothing to extend life; instead, they improve different endpoints. One endpoint is extending life, but as that is too difficult, drug companies instead show improvement in other endpoints — the most common being shrinking tumors.

Even after chemotherapy drugs are shown to provide no benefit but worse outcomes, the drugs are still not removed from the market by the FDA. This is because the FDA is not concerned about whether chemo drugs are effective. The drugs are profitable for pharmaceutical companies and cancer centers, and that is the objective of the FDA and other health authorities. This means that the government knows that many chemo drugs do nothing but continue to be reimbursed by Medicare.

What This All Means For Cancer Patients

Cancer patients don’t have anyone who advocates for their interests. The American Cancer Society, the FDA, the NIH, and all of the health authorities look out for the industry’s interests, not cancer patients’ interests. Therefore, the information they provide is not designed to educate cancer patients but is intended to provide information to cancer patients that result in being willing customers for the cancer centers and the associated pharma and medical device companies.

Cancer Patients Have a Very Limited Window to Select Their Treatment

Cancer patients must decide on the effectiveness of their recommended treatments before agreeing to a cure. Unfortunately, by the time treatment begins, it is exceedingly rare for the treatment to be stopped by the patient as inertia sets in.

Getting Accurate Independent Information

With any source on chemotherapy generally or Dexpak Taperpak specifically, cancer patients should ask themselves whether the individual or entity is independent.

Let’s take a look at a few they will deal with.

  1. The oncologist.
  2. The cancer center
  3. The FDA

The answer to each of these items is that none of them are independent, and they are tied into and part of the medical establishment. Therefore, they can’t also be independent of that medical establishment.

Let us try a second list of entities.

  1. WebMD
  2. Healthline
  3. The Mayo Clinic

Are these online sources of information independent?

The answer is no. These websites have a business model where drug companies and other medical entities pay them to carry information that they want them to carry. Going to these sites is undifferentiated from going to the websites of drug companies.